Mangoceuticals Inc. entered into Securities Purchase Agreements to sell 250 shares of Series B Convertible Preferred Stock for $250,000 and warrants for 330,000 shares of common stock, with plans to sell up to an additional $900,000 of shares and 1,188,000 warrants.